Wenyan Jiang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11379672/publications.pdf

Version: 2024-02-01

15	18,170	567144 15	996849 15
papers	citations	h-index	g-index

16	16	16	26733
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comprehensive Genome-wide Perturbations via CRISPR Adaptation Reveal Complex Genetics of Antibiotic Sensitivity. Cell, 2020, 180, 1002-1017.e31.	13.5	36
2	Prokaryotic single-cell RNA sequencing by in situ combinatorial indexing. Nature Microbiology, 2020, 5, 1192-1201.	5.9	103
3	Incomplete prophage tolerance by type III-A CRISPR-Cas systems reduces the fitness of lysogenic hosts. Nature Communications, 2018, 9, 61.	5.8	37
4	CRISPRâ€“Cas systems exploit viral DNA injection to establish and maintain adaptive immunity. Nature, 2017, 544, 101-104.	13.7	140
5	Impact of Different Target Sequences on Type III CRISPR-Cas Immunity. Journal of Bacteriology, 2016, 198, 941-950.	1.0	46
6	Degradation of Phage Transcripts by CRISPR-Associated RNases Enables Type III CRISPR-Cas Immunity. Cell, 2016, 164, 710-721.	13.5	194
7	CRISPR-Cas: New Tools for Genetic Manipulations from Bacterial Immunity Systems. Annual Review of Microbiology, 2015, 69, 209-228.	2.9	160
8	Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity. Cell, 2015, 161, 1164-1174.	13.5	367
9	Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nature Biotechnology, 2014, 32, 1146-1150.	9.4	718
10	Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting. Nature, 2014, 514, 633-637.	13.7	257
11	A Ruler Protein in a Complex for Antiviral Defense Determines the Length of Small Interfering CRISPR RNAs. Journal of Biological Chemistry, 2013, 288, 27888-27897.	1.6	123
12	Multiplex Genome Engineering Using CRISPR/Cas Systems. Science, 2013, 339, 819-823.	6.0	12,725
13	RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature Biotechnology, 2013, 31, 233-239.	9.4	2,071
14	Dealing with the Evolutionary Downside of CRISPR Immunity: Bacteria and Beneficial Plasmids. PLoS Genetics, 2013, 9, e1003844.	1.5	227
15	Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Research, 2013, 41, 7429-7437.	6.5	960